Navigation Links
Millennium Biotechnologies, Inc. Launches SURGEX(TM) the First Scientifically Validated Sports Nutritional Product Created from the Medical Markets
Date:11/26/2007

NBA, NFL and PGA Players Purchase SURGEX(TM) as Millennium Launches

http://www.surgexsports.com

BASKING RIDGE, N.J., Nov. 26 /PRNewswire/ -- Millennium Biotechnologies Inc., wholly-owned subsidiary of Millennium Biotechnologies Group, Inc. (OTC Bulletin Board: MBTG), a research-based nutraceutical company and a pioneer in the emerging field of specialized nutritional supplements for the medical market, announced today the launch of their advanced sports nutritional product, SURGEX(TM) (http://www.surgexsports.com). SURGEX(TM) was created from Millennium's extensive experience providing advanced nutritional formulas to some of the most prestigious medical institutions throughout the United States. The proprietary formula intends to meet the growing demand of elite level professional and amateur athletes and their coaches looking for nutritional support in a marketplace dominated by products with no clinical proof of benefit, unsubstantiated claims, excess protein, stimulants, and banned substances.

SURGEX(TM) has already caught the attention of numerous professional and collegiate athletes and teams. Many of which have made the switch to using SURGEX(TM) exclusively. Mike Curtis, current Strength and Conditioning Coach for the Memphis Grizzlies, uses SURGEX(TM) exclusively with the athletes he trains. Mr. Curtis adds, "The athletes I work with are some of the most well conditioned in the world. They require sophisticated nutritional support to aid in their recovery from intense year round training. My athletes are committed to finding ways to enhance their recovery and I believe SURGEX(TM) has played an integral role in that process."

SURGEX(TM) constitutes a blend of extended release proteins, anti- oxidants, amino acids and whole food calories to meet the multi-nutritional needs of Strength, Speed, and Endurance athletes. It works to counteract the stress that exercise puts on the body through an all-in-one nutritional supplement. During intense training, muscles incur cell damage and fatigue. The body tries to recover itself by automatically rebuilding that damage over time. If the muscles are re-trained before they have fully recovered, muscle repair and development can be inhibited, resulting in potential damage and decreased physical performance.

In double blind placebo controlled trials at the Rutgers University Human Performance Lab SURGEX(TM) significantly outperformed leading competitive products by assisting in reducing the damaging effects of exercise by improving peak power outputs, lowering oxidative stress/inflammatory markers, reducing fatigue (poor energy recovery) and the breakdown of muscle (post exercise wasting), as well as the lessening of free radical production (oxidative stress). The formula meets NCAA guidelines for use by collegiate athletes and is certified to contain no banned substances.

Supporting the launch is the debut of a state of the art website surgexsports.com. The state of the art site will provide a plethora of information on the science behind proper recovery from intense training and Millennium's study results supporting its claims for improving strength, endurance, oxidative stress markers and faster recovery. Visitors will also be able to order SURGEX(TM) for individual or team use on the site's online store.

"This is clearly a multibillion dollar industry worldwide and to leverage our proven, patent protected formulas, in a global sports market place will significantly enhance share holder value. With over twenty professional basketball players currently using our product, some for over a year, we believe that this will ignite a strong demand across numerous sports channels worldwide," said Mark Mirken, Chief Operating Officer of Millennium Biotechnologies.

About Millennium:

Millennium's three proprietary, marketed products, which form the Company's Resurgex(R) Continuum of Care, include Resurgex Select(R), Resurgex(R), and Resurgex Plus(R). Resurgex Select(R) is a whole foods-based, calorically dense, high-protein nutritional formula developed for cancer patients undergoing chemotherapy or radiation treatments. Resurgex(R) and Resurgex Plus(R) are specialized, anabolic nutritional supplements rich in antioxidants that provide nutritional support post-treatment. Millennium is also recently developed a SURGEX(TM) sports nutrition formula, clinically proven to address the nutritional concerns of both professional and amateur elite athletes. These athletes often experience similar symptoms post-workout to those battling immunocompromised conditions, such as fatigue, loss of lean muscle, oxidative stress, and reduced immune function.

Statements in this news release regarding future financial and operating results, future growth in R&D programs, potential applications of the Company's technology, opportunities for the Company, and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward- looking statements including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of the Company's intellectual property, and economic conditions generally. Additional information on potential factors that could affect results and other risks and uncertainties are detailed from time to time in the Company's periodic reports, including Forms 10-KSB, 10-QSB, 8-K, and other forms filed with the Securities and Exchange Commission ("SEC").


'/>"/>
SOURCE Millennium Biotechnologies Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Thomas Weisel Partners 2007 Healthcare Conference To Webcast Millennium Presentation
2. Millennium Biotechnologies Group, Inc. (MBTG.OB) Announces Completion of $2,277,000 Equity Financing
3. Millennium Biotechnologies Group, Inc. (MBTG.OB) Announces Appointment of Mark C. Mirken as its President and Chief Operating Officer
4. Merrill Lynch Global Pharmaceutical, Biotech and Medtech Conference to Webcast Millennium Presentation
5. Life Sciences Leader Joins Millennium Board of Directors
6. Millennium to Webcast Third-Quarter 2007 Financial and Operational Results
7. Millennium Reports Outstanding Third-Quarter Results Driven by VELCADE(R) (Bortezomib) for Injection Sales
8. Millennium Research Group Offers New Marketrack Service that Tracks European Dental Implant Market
9. Microchip Biotechnologies, Inc. Secures Exclusive License to Use New University of Alberta Technology for Developing Microfluidic Devices
10. Maven Biotechnologies, LLC to Present at BIOCOM Investor Conference
11. Research Triangle Area Health Care Collaborative Launches Bridges to Excellence(R) Initiative to Improve Quality and Lower Costs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... -- Neogen Corporation (NASDAQ: NEOG ) announced ... as its chief science officer — a new position ... Neogen effective Jan. 1. Kephart has served ... of Thermo Fisher Scientific, as well as animal health ... industry experience also includes the management of a team ...
(Date:12/7/2016)... , Dec. 7, 2016  Nordion, a ... General Atomics (GA), welcome today,s award by the ... Security Administration (NNSA) of the Phase II cooperative ... with Nordion and the University of Missouri Research ... funding will support the establishment of a new, ...
(Date:12/7/2016)... , Dec. 7, 2016  Vyriad Inc. announced today ... the company,s Board of Directors. "We are ... build our business and develop our oncolytic viruses as ... said Stephen Russell , MD, PhD, CEO of ... share our vision and passion for making a difference ...
(Date:12/7/2016)... YORK and ANN ARBOR, Mich. ... privately held biopharmaceutical company developing breakthrough immune modulatory medicines, ... trial of the Company,s lead therapeutic candidate, LYC-30937- E ... is often a debilitating skin disease that is estimated ... the United States , with approximately 1.5 ...
Breaking Biology Technology:
(Date:12/7/2016)... According to a new market research report "Emotion Detection and Recognition Market ... Application Area, End User, And Region - Global Forecast to 2021", published by ... 2016 to USD 36.07 Billion by 2021, at a Compound Annual Growth Rate ... ... MarketsandMarkets Logo ...
(Date:12/6/2016)... Valencell , the leading innovator in ... a third consecutive year of triple digit growth for ... with a 360 percent increase in companies who have ... driven by sales of its wrist and ear Benchmark™ ... technology for hearables for fitness and healthcare applications. ...
(Date:11/30/2016)... , Nov. 30, 2016 Not many of us realize that we spend ... recovery so we need to do it well. Inadequate sleep levels have been found ... pressure, stroke, diabetes, and even cancer. Maybe now is the best time ... could help them to manage their sleep quality? Continue ... ...
Breaking Biology News(10 mins):